Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Valeant Will Release Third-Quarter 2017 Financial Results On November 7

Valeant Pharmaceuticals International,Inc.
Posted on: 03 Oct 17
Valeant Will Release Third-Quarter 2017 Financial Results On November 7

PR Newswire

LAVAL, Quebec, Oct. 3, 2017

LAVAL, Quebec, Oct. 3, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") will release its third-quarter 2017 financial results on Tuesday, Nov. 7, 2017. Valeant will host a conference call and live web cast at 8:00 a.m. EST to discuss the results and provide a business update. All materials will be made available on the investor relations section of the Valeant web site prior to the start of the call.

Conference Call Details


Tuesday, Nov. 7, 2017


8:00 a.m. EST


Participant Event Dial-in: 

(844) 428-3520 (North America)

(409) 767-8386 (International) 

Participant Passcode:


Replay Dial-in:

(855) 859-2056 (North America)

(404) 537-3406 (International) 

Replay Passcode:

91700211 (replay available until Jan. 7, 2018)

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at

Investor Contact:

Media Contact:

Arthur Shannon

Lainie Keller

(514) 856-3855

(908) 927-0617

(877) 281-6642 (toll free)


View original content with multimedia:

SOURCE Valeant Pharmaceuticals International, Inc.

PR Newswire

Last updated on: 03/10/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.